Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Short-term Investments: 2022-2025

Historic Short-term Investments for Whitehawk Therapeutics (WHWK) over the last 3 years, with Sep 2025 value amounting to $124.7 million.

  • Whitehawk Therapeutics' Short-term Investments rose 288.59% to $124.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.7 million, marking a year-over-year increase of 288.59%. This contributed to the annual value of $18.6 million for FY2024, which is 59.60% down from last year.
  • Latest data reveals that Whitehawk Therapeutics reported Short-term Investments of $124.7 million as of Q3 2025, which was up 286.39% from $32.3 million recorded in Q2 2025.
  • In the past 5 years, Whitehawk Therapeutics' Short-term Investments ranged from a high of $133.5 million in Q4 2022 and a low of $3.5 million during Q1 2025.
  • Its 3-year average for Short-term Investments is $51.2 million, with a median of $37.4 million in 2024.
  • Over the last 5 years, Whitehawk Therapeutics' Short-term Investments had its largest YoY gain of 288.59% in 2025, and its largest YoY loss of 89.87% in 2025.
  • Quarterly analysis of 4 years shows Whitehawk Therapeutics' Short-term Investments stood at $133.5 million in 2022, then tumbled by 65.59% to $46.0 million in 2023, then slumped by 59.60% to $18.6 million in 2024, then surged by 288.59% to $124.7 million in 2025.
  • Its last three reported values are $124.7 million in Q3 2025, $32.3 million for Q2 2025, and $3.5 million during Q1 2025.